Henry Ford Health enrolls first patients in BioCardia's Phase 3 CardiAMP HF II trial

BioCardia, Inc.

Henry Ford Health (Detroit) is now enrolling ischemic HFrEF patients in BioCardia's pivotal CardiAMP HF II trial.
CardiAMP HF II is a 250-patient randomized, placebo-controlled confirmatory study of autologous bone marrow cell therapy.
Primary composite endpoint includes all-cause death, nonfatal MACE, and quality of life; prior CardiAMP HF trial met significance for elevated NTproBNP patients.
Therapy involves same-day cell harvest, bedside processing, and minimally invasive catheter delivery.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.